For this reason, 5-FU is nearly always administered with LV (N5-formyl tetrahydrofolate) or newer reduced folate analogs that do not require metabolism[14] for cancer treatment to promote TS inhibition despite 5-FU’s inefficient conversion to FdUMP[15]. The gene discussed is TYMS; the disease is cancer.